Phragmitis Rhizoma Extract Mitigates Anticancer-Induced Bone Marrow Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents lack selectivity for cancer cells, resulting in significant side effects such as hematopoietic toxicity, which can lead to bone marrow suppression and other adverse effects.
Innovation Solution
A composition containing Phragmitis Rhizoma extract as an active ingredient is developed to prevent, ameliorate, or treat disorders caused by side effects of anticancer agents, specifically hematopoietic toxicity, by significantly restoring hematopoietic stem and progenitor cell survival and recovering bone marrow suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer agents are used to eradicate cancer cells, then therapeutic effect on cancer cells is improved, but toxic effect on normal cells increases
Solution Approach 1:
Phragmitis Rhizoma extract serves as a protective intermediary substance that mitigates the harmful effects of anticancer agents on normal cells. The extract contains bioactive compounds that protect bone marrow cells and other healthy tissues from chemotherapy-induced toxicity, thereby reducing side effects while maintaining the anticancer agent's therapeutic efficacy.
Solution Approach 2:
The invention combines Phragmitis Rhizoma extract with anticancer agents to create a composite therapeutic formulation. This composite approach leverages the protective properties of the plant extract alongside the cytotoxic effects of the anticancer agent, achieving a synergistic effect that enhances therapeutic outcome while minimizing adverse reactions.
2Productivity
If anticancer agents are administered to extend survival time, then productivity is improved, but side effects such as bone marrow suppression increase
Solution Approach 1:
Phragmitis Rhizoma extract acts as a protective intermediary that specifically safeguards bone marrow cells from chemotherapy-induced suppression. The extract contains compounds that promote hematopoietic recovery and protect stem cells, enabling patients to tolerate higher doses or longer durations of anticancer therapy without severe bone marrow toxicity.
Solution Approach 2:
The Phragmitis Rhizoma extract is administered to preemptively counteract the bone marrow suppressive effects of anticancer agents. By providing protective action before and during chemotherapy treatment, the extract prevents or reduces the development of hematopoietic toxicity, allowing for more aggressive and effective cancer treatment regimens.
Data Source
Figure 1
Figure 2(A)~2(B)
Figure 3(A)~3(E)
AI summary
The present invention relates to a composition containing Phragmitis Rhizoma extract as an active ingredient for prevention, amelioration, or treatment of a disorder caused by side effect of an anticancer agent. As a result of treating mouse bone marrow cells with an extract of Phragmitis Rhizoma, it was confirmed to have an effect that a decrease in colony of hematopoietic cells, which is induced by an anticancer agent, is significantly recovered and bone marrow suppression caused by an anticancer agent is significantly recovered in an animal model which has been induced to have bone marrow suppression according to intraperitoneal injection of an anticancer agent. Thus, the Phragmitis Rhizoma extract of the present invention can be advantageously used for a composition for prevention, amelioration, or treatment of a disorder caused by side effect of an anticancer agent, and there is a possibility of having the increased effect of an anticancer agent when it is used as an anticancer adjuvant in combination with an anticancer agent.